Last reviewed · How we verify
IL-7/IL-15 pre-treated CD19 cells
IL-7/IL-15 pre-treated CD19-targeted CAR-T cells enhance T cell proliferation and persistence to attack CD19-positive B-cell malignancies.
IL-7/IL-15 pre-treated CD19-targeted CAR-T cells enhance T cell proliferation and persistence to attack CD19-positive B-cell malignancies. Used for B-cell malignancies expressing CD19 (e.g., acute lymphoblastic leukemia, diffuse large B-cell lymphoma).
At a glance
| Generic name | IL-7/IL-15 pre-treated CD19 cells |
|---|---|
| Sponsor | jiangjingting |
| Drug class | CAR-T cell therapy |
| Target | CD19 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
This is an engineered cell therapy where CD19-targeting CAR-T cells are pre-treated with interleukin-7 (IL-7) and interleukin-15 (IL-15) to boost their expansion, survival, and anti-tumor function. IL-7 and IL-15 are cytokines that promote T cell proliferation and memory formation, improving the therapeutic potency of the CAR-T product. The resulting cells recognize and eliminate CD19-expressing B-cell tumors.
Approved indications
- B-cell malignancies expressing CD19 (e.g., acute lymphoblastic leukemia, diffuse large B-cell lymphoma)
Common side effects
- Cytokine release syndrome
- Neurotoxicity
- Cytopenias
- Infections
Key clinical trials
- CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (PHASE1, PHASE2)
- Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IL-7/IL-15 pre-treated CD19 cells CI brief — competitive landscape report
- IL-7/IL-15 pre-treated CD19 cells updates RSS · CI watch RSS
- jiangjingting portfolio CI